|
1
|
Saeed A, Park R and Sun W: The integration
of immune checkpoint inhibitors with VEGF targeted agents in
advanced gastric and gastroesophageal adenocarcinoma: A review on
the rationale and results of early phase trials. J Hematol Oncol.
14:132021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murphy M and Stordal B: Erlotinib or
gefitinib for the treatment of relapsed platinum pretreated
non-small cell lung cancer and ovarian cancer: A systematic review.
Drug Resist Updat. 14:177–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah NP, Nicoll JM, Nagar B, Gorre ME,
Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase
domain mutations confer polyclonal resistance to the tyrosine
kinase inhibitor imatinib (STI571) in chronic phase and blast
crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yotaro O: Genetic landscape of chronic
myeloid leukemia. Int J Hematol. 117:30–36. 2023. View Article : Google Scholar
|
|
5
|
Druker BJ, Talpaz M, Resta DJ, Peng B,
Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R,
Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Honda H, Ushijima T, Wakazono K, Oda H,
Tanaka Y, Aizawa Si, Ishikawa T, Yazaki Y and Hirai H: Acquired
loss of p53 induces blastic transformation in
p210(bcr/abl)-expressing hematopoietic cells: a transgenic study
for blast crisis of human CML. Blood. 95:1144–1150. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Deiry WS, Sigman CC and Kelloff GJ:
Imaging and oncologic drug development. J Clin Oncol. 24:3261–3273.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang BB, Liu JG, Bai XY, Huang YJ, Xu N
and Ren T: A novel fluorescent dye invades mitochondria to
selectively kill cancer stem cells via increased ROS production.
Bioinorg Chem Appl. 2021:47639442021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alencar H, Funovics MA, Figueiredo J,
Sawaya H, Weissleder R and Mahmood U: Colonic adenocarcinomas:
Near-infrared microcatheter imaging of smart probes for early
detection-study in mice. Radiology. 244:232–238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang B, Yu F, Li P, Tong L, Duan X, Xie T
and Wang X: A near-infrared neutral pH fluorescent probe for
monitoring minor pH changes: Imaging in living HepG2 and HL-7702
cells. J Am Chem Soc. 131:3016–3023. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borah A, Raveendran S, Rochani A, Maekawa
T and Kumar DS: Targeting self-renewal pathways in cancer stem
cells: Clinical implications for cancer therapy. Oncogenesis.
4:e1772015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Henderson T, Chen M, Darrow MA, Li CS,
Chiu CL, Monjazeb AM, Murphy WJ and Canter RJ: Alterations in
cancer stem-cell marker CD44 expression predict oncologic outcome
in soft-tissue sarcomas. J Surg Res. 223:207–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Ma H, Zhang J, Zhu L, Wang C and
Yang Y: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem
cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sudhalkar N, Rathod NP, Mathews A, Chopra
S, Sriram H, Shrivastava SK and Goda JS: Potential role of cancer
stem cells as biomarkers and therapeutic targets in cervical
cancer. Cancer Rep (Hoboken). 2:e11442019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krause DS and Van Etten RA: Right on
target: Eradicating leukemic stem cells. Trends Mol Med.
13:470–481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schürch C, Riether C, Matter MS, Tzankov A
and Ochsenbein AF: CD27 signaling on chronic myelogenous leukemia
stem cells activates Wnt target genes and promotes disease
progression. J Clin Invest. 122:624–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jamieson CHM, Ailles LE, Dylla SJ,
Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating
A, et al: Granulocyte-macrophage progenitors as candidate leukemic
stem cells in blast-crisis CML. N Engl J Med. 351:657–667. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishikawa K, Takenaga K, Akimoto M,
Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y and Hayashi
J: ROS-generating mitochondrial DNA mutations can regulate tumor
cell metastasis. Science. 320:661–664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kroemer G and Reed JC: Mitochondrial
control of cell death. Nat Med. 6:513–519. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scheel C, Eaton EN, Li SH, Chaffer CL,
Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL and
Weinberg RA: Paracrine and autocrine signals induce and maintain
mesenchymal and stem cell states in the breast. Cell. 145:926–940.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang C, Liu T, Su Y, Luo S, Zhu Y, Tan X,
Fan S, Zhang L, Zhou Y, Cheng T and Shi C: A near-infrared
fluorescent heptamethine indocyanine dye with preferential tumor
accumulation for in vivo imaging. Biomaterials. 31:6612–6617. 2010.
View Article : Google Scholar : PubMed/NCBI
|
